

Clinical Trial Protocol

Iranian Registry of Clinical Trials

06 Jul 2026

Comparison of the therapeutic effect of conjugated estrogen vaginal cream with vitamin D and E combination vaginal cream in the treatment of postmenopausal genital syndrome

Protocol summary

Study aim

Comparison of the therapeutic effect of conjugated estrogen vaginal cream with vitamin D and E combination vaginal cream in the treatment of postmenopausal genital syndrome

Design

Phase 3 Randomized Clinical trial on 64 patients. samples will be randomly assigned to two intervention and control groups.

Settings and conduct

This double blind study will be conducted in Fatemieh Hospital affiliated to Hamadan University of Medical Sciences. In this study, the coverage of the ointments will be made in different colors, the prescribing physician and the patient will be unaware of the content inside them.

Participants/Inclusion and exclusion criteria

Participants are postmenopausal women with genital urinary syndrome include vaginal dryness, burning and itching of the vagina, dyspareunia, and urinary symptoms of burning and frequent urination. Conditions for not entering the study include: definitive or suspected endometrial or breast cancer, abnormal vaginal bleeding or vaginal infection, a history of diabetes, CKD, arthritis, cardiovascular disease and active hepatobiliary disease, sensitivity to vitamin E, D or estrogen. women who have had hormone therapy for the past 12 weeks and women whose husbands have a sexual dysfunction.

Intervention groups

In the intervention group, patients will be treated with a combination vaginal cream containing Vitamin D 1000 IU / dose and Vitamin E 100 IU / dose with daily once a day for 2 weeks and then three times a week for 10 weeks. In the control group, patients will be treated with 0.625 g / dose estrogen conjugated vaginal cream (1 g of estromarin produced by Abu Reihan Pharmaceutical Company, equivalent to a quarter of a 4 g applicator)

once a day for 2 weeks, followed by three times a week for 10 weeks.

Main outcome variables

Primary outcome of study will be changes in genital urinary symptoms and secondary outcome patients' marital quality of life.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20151123025202N10**

Registration date: **2020-06-22, 1399/04/02**

Registration timing: **prospective**

Last update: **2020-06-22, 1399/04/02**

Update count: **0**

Registration date

2020-06-22, 1399/04/02

Registrant information

Name

Abbas Moradi

Name of organization / entity

Hamedan University of Medical Of Science

Country

Iran (Islamic Republic of)

Phone

+98 81 3838 0097

Email address

a.moradi@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-07-21, 1399/04/31

Expected recruitment end date

2022-07-21, 1401/04/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the therapeutic effect of conjugated estrogen vaginal cream with vitamin D and E combination vaginal cream in the treatment of postmenopausal genital syndrome

Public title

Treatment of postmenopausal genital syndrome

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

postmenopausal women Has urinary-genital symptoms: vaginal itching, burning, dryness, dyspareunia, urination frequency and burning

Exclusion criteria:

Definitely or suspected of having endometrial or breast cancer Women with abnormal vaginal bleeding or vaginal infection Women with Diabetes, CKD, Arthritis, Cardiovascular Disease and Active Hepatobiliary Disease Sensitivity to vitamin E, D or vaginal estrogen Women have spouses with sexual dysfunction Women who have been on hormone therapy for the past 12 weeks

Age

From **45 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **64**

Randomization (investigator's opinion)

Randomized

Randomization description

We made 64 cards and write letter I on 32 for Intervention and on the other 32 letter C for the control group. Then put them inside the envelope with aluminum wrap and put in a box. At the time of patient arrival, one of the envelopes randomly will be selected and will be opened, based on selected letter (I or C) patients will be assigned to intervention or control group.

Blinding (investigator's opinion)

Double blinded

Blinding description

Vaginal creams will be in prepared in two different colors. Neither the patients nor the prescribing physician will be aware of the active ingredient in the cream. When analyzing data, group code is revealed.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Hamadan University of Medical Science

Street address

Shahid Fahmideh Avenue

City

Hamedan

Province

Hamadan

Postal code

6517838697

Approval date

2020-05-22, 1399/03/02

Ethics committee reference number

IR.UMSHA.REC.1399.220

Health conditions studied**1****Description of health condition studied**

Genital urinary syndrome in postmenopausal women

ICD-10 code

N95

ICD-10 code description

Menopausal and other perimenopausal disorders

Primary outcomes**1****Description**

Changes in urinary-genital symptoms

Timepoint

Week 4, 12 and 16 after treatment onset

Method of measurement

Get a history and clinical examination

Secondary outcomes**1****Description**

Marital Quality of life

Timepoint

16 weeks after treatment onset

Method of measurement

Intervention groups

1

Description

Intervention group: This group will be treated with a combination vaginal cream containing Vitamin D 1000 IU / dose and Vitamin E 100 IU / dose once a day for 2 weeks and followed by three times a week for 10 weeks

Category

Treatment - Drugs

2

Description

Control group: Patients in this group will be treated with 0.625 g / dose estrogen conjugated vaginal cream (1 gram of estrogen produced by Abu Reihan Pharmaceutical Company, equivalent to a quarter of a 4 g applicator) once a day for 2 weeks and followed by three times a week for 10 weeks

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Fatemieh Hospital

Full name of responsible person

Dr Nahid Radnia

Street address

Pasdaran

City

Hamedan

Province

Hamadan

Postal code

6517789971

Phone

+98 81 1827 7459

Fax

+98 81 1828 3939

Email

fatemieh@umsha.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Hamedan University of Medical Sciences

Full name of responsible person

Dr Saeid Bashirian

Street address

Shahid Fahmideh Ave

City

Hamedan

Province

Hamadan

Postal code

6517838677

Phone

+98 81 3838 0717

Fax

+98 81 3838 0130

Email

vc_research@umsha.ac.ir

Web page address

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Hamedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Hamedan University of Medical Sciences

Full name of responsible person

Abbas Moradi

Position

Coach

Latest degree

Master

Other areas of specialty/work

Epidemiology

Street address

Shahid Fahmideh Ave

City

Hamedan

Province

Hamadan

Postal code

6517838736

Phone

+98 81 3838 0097

Fax

+98 81 3838 0208

Email

a.moradi@umsha.ac.ir

Person responsible for scientific

inquiries

Contact

Name of organization / entity

Hamedan University of Medical Sciences

Full name of responsible person

Dr Nahid Radnia

Position

Associate Professor of Obstetrics and Gynecology

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Pasdaran Ave

City

Hamedan

Province

Hamadan

Postal code

6517789971

Phone

+98 81 1827 7459

Email

n.radnia@umsha.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Hamedan University of Medical Sciences

Full name of responsible person

Abbas Moradi

Position

Coach

Latest degree

Master

Other areas of specialty/work

Epidemiology

Street address

Shahid fahmideh Ave

City

Hamedan

Province

Hamadan

Postal code

6517838736

Phone

+98 81 3838 0097

Fax

+98 81 3838 0208

Email

a.moradi@umsha.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Not applicable

Analytic Code

Not applicable

Data Dictionary

Not applicable